RU-22930

In this article, we are going to address the topic of RU-22930 from different perspectives and angles, with the aim of providing a comprehensive and complete view on this topic. We will analyze its impact in different contexts, its evolution over time, as well as the different opinions and positions that exist on the matter. RU-22930 is a topic of current relevance that arouses great interest and debate, which is why it is essential to address it in a rigorous and exhaustive manner. Through this article, we aim to offer our readers a detailed and enriching vision of RU-22930, with the aim of contributing to the knowledge and understanding of this particular topic.

RU-22930
Clinical data
Other names5,6-Dihydro-2-methyl-4--2H-1,2,4-oxadiazin-3-(4H)-one[1]
Drug classNonsteroidal antiandrogen
Identifiers
  • 2-Methyl-4--1,2,4-oxadiazinan-3-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H10F3N3O4
Molar mass305.213 g·mol−1
3D model (JSmol)
  • CN1OCCN(C1=O)C1=CC=C(C(=C1)C(F)(F)F)N(=O)=O
  • InChI=1S/C11H10F3N3O4/c1-15-10(18)16(4-5-21-15)7-2-3-9(17(19)20)8(6-7)11(12,13)14/h2-3,6H,4-5H2,1H3
  • Key:SQAORNVRAYTOMS-UHFFFAOYSA-N

RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed.[2][3] It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis.[2] Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.[2][4]

See also

References

  1. ^ "Compositions and methods for inhibiting the action of androgens".
  2. ^ a b c Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol. Ther. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-x. PMID 6205409.
  3. ^ Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363.
  4. ^ Thomson, D. S. (1989). "Pharmacology of Anti-androgens in the Skin". Pharmacology of the Skin II. Handbook of Experimental Pharmacology. Vol. 87 / 2. pp. 483–493. doi:10.1007/978-3-642-74054-1_36. ISBN 978-3-642-74056-5. ISSN 0171-2004.



Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.